Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Wednesday morning. The firm issued a sell rating on the medical research company’s stock.

Organovo Trading Down 32.6 %

Shares of ONVO stock opened at $0.27 on Wednesday. The firm has a fifty day moving average price of $0.43 and a 200 day moving average price of $0.44. The company has a market cap of $4.67 million, a P/E ratio of -0.32 and a beta of 0.45. Organovo has a 12 month low of $0.25 and a 12 month high of $1.83.

Shares of Organovo are scheduled to reverse split on Friday, March 21st. The 1-12 reverse split was announced on Wednesday, March 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, March 20th.

Organovo (NASDAQ:ONVO) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. On average, equities analysts forecast that Organovo will post -0.77 EPS for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.